BioCentury | Oct 23, 2020
Product Development

What’s next for targeted protein degradation

...– IKAROS family zinc finger 3 BCR-ABLBCR-ABL tyrosine kinase Btk...
BioCentury | May 13, 2020
Product Development

Gilead secures global access to remdesivir via generic manufacturing deals

...Exvastat Ltd. in Ireland will test Gleevec imatinib in a randomized, double-blind clinical trial. The BCR-ABL...
...million to upgrade the NRC’s Montreal facility to comply with GMP standards. Targets BCR-ABL - BCR-ABL tyrosine kinase...
BioCentury | Jan 29, 2020
Distillery Therapeutics

WWTR1-AXL-ABL2 axis inhibition for brain metastases in lung cancer

...shRNAs against WWTR1 or AXL reduced disease burden in the brain. Asciminib, an inhibitor of BCR-ABL tyrosine kinase (BCR-ABL)...
...ALL). TARGET/MARKER/PATHWAY: ABL proto-oncogene 2 non-receptor tyrosine kinase (ABL2); AXL receptor tyrosine kinase (AXL; UFO); BCR-ABL tyrosine kinase (BCR-ABL)...
BioCentury | Nov 18, 2019

Tyrosine kinase inhibitors for the treatment of pemphigus

...DISEASE CATEGORY: Autoimmune disease INDICATION: Pemphigus Tyrosine kinase inhibitors including the dual BCR-ABL/c-Kit inhibitor imatinib could...
...IgG deposition in the epidermis; and imatinib prevented hair loss, a consequence of pemphigus. TARGET/MARKER/PATHWAY: BCR-ABL tyrosine kinase (BCR-ABL)...
...STI-571) Agency for Science Technology and Research Kyoto University Stem cell factor (SCF) receptor tyrosine kinase (c-Kit) (KIT) (CD117) BCR-ABL tyrosine kinase (BCR-ABL) Desmoglein...
BioCentury | Oct 28, 2019
Financial News

After Hong Kong IPO lull, local demand lifts Ascentage offering

...eight clinical-stage small molecules, including HQP1351 and two other next-generation kinase inhibitors. HQP1351, which inhibits BCR-ABL...
...in preclinical and clinical studies (see “MD Anderson Collaborating with Ascentage” ). Targets: BCR-ABL - BCR-ABL tyrosine kinase...
BioCentury | Aug 15, 2019
Finance

Deciphera’s $400M follow-on adds firepower on strength of GIST readout

...to treat malignancies including tenosynovial giant cell tumors; rebastinib, an inhibitor of FLT1, Tie2 and BCR-ABL tyrosine kinase...
BioCentury | Jul 3, 2019
Preclinical News

Controlling CAR T toxicity with BMS's Sprycel

...Bristol-Myers Squibb Co. (NYSE:BMY) could block CRS by reversibly pausing CAR T cell activity. The BCR-ABL tyrosine kinase (BCR-ABL)...
...markets Sprycel for acute lymphoblastic leukemia (ALL) and chronic myelogenous leukemia (CML). Targets: BCR-ABL - BCR-ABL tyrosine kinase...
BioCentury | Jun 14, 2019
Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

...Arzerra ofatumumab Human mAb against CD20 Multiple sclerosis Ph III Asciminib Small molecule inhibitor of BCR-ABL tyrosine kinase (BCR-ABL)...
BioCentury | May 15, 2019
Distillery Therapeutics

Inhibiting PIM2 sensitizes CML to Gleevec

...sample, cell culture and mouse studies suggest inhibiting PIM2 could sensitize CML to the dual BCR-ABL/c-Kit...
...LLC has the oral PIM2 inhibitor JP-11646 in preclinical testing for MM. TARGET/MARKER/PATHWAY: Pim-2 (PIM2); BCR-ABL tyrosine kinase (BCR-ABL)...
...Michael.Green@umassmed.edu Claire Quang Gleevac, Gleevec, Glivec, imatinib mesylate (QTI571, CGP 57148B, Ruvise, STI-571) PIM447, lgh447 University of Massachusetts Medical School BCR-ABL tyrosine kinase (BCR-ABL) Pim-2...
BioCentury | Feb 26, 2019
Distillery Therapeutics

Cancer

...Squibb Co. and Otsuka Pharmaceutical Co. Ltd. market Sprycel, an oral small molecule inhibitor of BCR-ABL...
Items per page:
1 - 10 of 729